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10-MINUTE CONSULTATION
Poor adherence to antihypertensive drugs
Mohammed Awais Hameed clinical research fellow 1 2, Indranil Dasgupta consultant nephrologist 1,
Paramjit Gill reader in primary care research 3
1Heart of England NHS Foundation Trust, Birmingham, UK; 2Institute of Applied Health Research, University of Birmingham, UK; 3Primary Care
Clinical Sciences, University of Birmingham, UK
A 56 year old man has had persistently raised blood pressure
readings at home and in clinic since his diagnosis of
hypertension three years ago. Hewas diagnosed after ambulatory
blood pressure monitoring, and is prescribed four
antihypertensives. At a routine blood pressure review he says
not to bother with another prescription because he doesn’t take
the drugs.
As many as half of patients with apparent resistant hypertension
do not take their prescribed drugs.1 Consider non-adherence in
those taking antihypertensives with elevated blood pressure
readings particularly in those with apparent resistant
hypertension, where blood pressure is persistently ≥140/90 mm
Hg despite taking ≥3 titrated antihypertensive drugs including
a diuretic. Biological resistant hypertension affects around 10%
of those treated for hypertension in the United Kingdom, and
such patients need specialist management. Attempt to identify
and manage poor adherence before referring the patient to a
specialist.
What you should do
To find out about adherence to drugs ask patients questions such
as: “I knowmany people have difficulty taking their medicines,
how do you manage yours?” or “Take me through your
medications.”
The rate that patients are prescribed or collect their drugs can
also provide information on adherence. In patients whose blood
pressure remains uncontrolled despite multiple (≥3)
antihypertensive drugs consider referral to a specialist
hypertension clinic for directly observed therapy, where a patient
is observed taking their drugs while having their blood pressure
measured during and afterwards,1 or toxicological analysis of
urine.2 Explore to what extent and why the patient is not taking
the prescribed drugs. The table shows factors identified in
observational studies that are associated with non-adherence
and could provide a framework for discussion.3 If the patient
declines treatment you can explain: “I respect your decision not
to take drugs for your blood pressure, but I would like to explore
the reasons behind this decision so that I can support you in this
choice.”
What you should cover
Discuss risk
Hypertension is generally an asymptomatic condition and
patients might not understand the clinical course of hypertension
and the reduced risk of harmful consequences with lifestyle and
medical therapies. The risk associated with increasing blood
pressure is continuous. Each 2 mm Hg rise in systolic blood
pressure is associated with a 7% increased risk of death from
ischaemic heart disease, and a 10% increased risk of death from
stroke for people aged 40-69 years.4 Avoid using descriptive
terms when explaining risks to patients. Use absolute numbers
with visual aids and consistent denominators. For example, “In
a population of 100 people aged 40-69, with every 2 mm Hg
rise in blood pressure, 10 people are at risk of dying from a
stroke and seven people are at a risk of dying from heart disease
such as a heart attack.”
To help patients understand what that means for them calculate
their QRISK2 score (https://qrisk.org). For example, the QRISK
for a 56 year old man with no other associated risks is 7.9%
over 10 years. This can be explained by: “In a crowd of 100
people with the same risk factors as you, eight are likely to have
a heart attack or a stroke in the next 10 years.” Supplement this
information by showing patients the visual representation of
their estimated risk displayed on the QRISK website (fig 1⇓).
Discuss lifestyle
If “medication burden”—taking large numbers of drugs— is
identified as a contributing factor to a patient’s suboptimal
adherence, then it might help to revisit lifestyle changes that
help lower blood pressure with him or her. Talk about the blood
pressure reductions that might be expected from different
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What you need to know
• Non-adherence to antihypertensives and other drugs is common
• If you identify non-adherence, discuss risks of untreated hypertension, expected benefits of drugs that lower blood pressure, and
lifestyle changes using the patient’s personalised risk
• Negotiate an achievable goal with the patient
lifestyle modifications. A reduction in salt intake of 4.4 g/day
on average reduces blood pressure by 5/3 mm Hg
(systolic/diastolic).5 Two medium slices of white bread, two
rashers of bacon, a packet of crisps, and half a cupful of baked
beans altogether contain 4.4 g of salt. A systematic review and
meta-analysis showed that three to four sessions of 40 minutes
of aerobic exercise at a moderate intensity, on average, lowers
blood pressure by 5/3 mm Hg.6 7 One randomised controlled
trial showed that each pound (0.45 kg) of weight loss reduced
blood pressure by about 1 mm Hg in overweight or obese
people.8 The DASH (dietary approaches to stop hypertension)
diet is high in vegetables, fruits, low fat dairy products, whole
grains, poultry, fish, and nuts and low in sweets, sugar sweetened
beverages, and red meats.9 One randomised controlled trial
showed a 6/4 mm Hg reduction in blood pressure when the
DASH diet was compared with a control diet that was typical
of the diets of a substantial number of US citizens. Dealing with
multiple lifestyle modifications simultaneously has been shown
to be more effective than a sequential approach,10 and may have
a cumulative effect on blood pressure reduction.
Discuss medication
Determine how the patient is managing his or her drugs. Pay
particular attention to the side effects of the drugs, the dosing
frequency, and number of different drugs. A reduction in the
number of drugs could be negotiated, aiming for a higher, more
realistic blood pressure target. The expected blood pressure
reductions achieved on drugs can be quoted on the basis of a
meta-analysis of 147 randomised controlled trials.11 It depends
on the patient’s pretreatment blood pressure and the number of
drugs taken. For example, a patient with a pretreatment blood
pressure of 178/98 mm Hg may expect reductions of 11.7/4.6
mmHg, 22.2/11.0 mmHg, and 31.7/15.6 mmHg if treated with
standard doses of one, two, or three antihypertensives,
respectively.11
Consider simplifying the patient’s drug regimen. Complicated
dosing regimens are associated with lower adherence.12 Fewer
daily doses, monotherapy, and fewer changes in
antihypertensives could be considered. A meta-analysis has
shown that single pill combination drugs are associated with
improved adherence and blood pressure control, and they could
be used where patients are prescribed multiple antihypertensive
drugs.13
Set a goal
Empowering patients to monitor their blood pressure at home
and to manage their drugs improves blood pressure control.14
Consider motivational interviewing, which has been shown to
improve adherence to antihypertensives and blood pressure
control.15 This involves getting patients to explore why and how
they can change their behaviours. The healthcare provider’s
role is to guide patients through setting the agenda for change
by eliciting their internal motivation to change:
• Ask open ended questions so patients can consider how
and why they might change
• Listen to patients’ accounts and express empathy
• Inform by asking permission to provide information
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Useful reading
For patients
AmericanHeart Association. Resistant hypertension. www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/
Resistant-Hypertension_UCM_469327_Article.jsp
For health professionals
Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. BMJ 2012;345:e7473
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147
randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
Rollnick S, Butler CC, Kinnersley P, et al. Motivational interviewing. BMJ 2010;340:c1900
QRISK. QRISK2 calculator. https//qrisk.org
Education into practice
• Do you explore adherence in patients with apparently poorly controlled hypertension?
How patients were involved in the creation of this article
No patients were involved in the creation of this article
Table
Table Table| Factors contributing to non-adherence in hypertension with possible solutions. Adapted from WHO report on adherence to
long term therapies3
Possible solutionsFactors
Socioeconomic
Make patients aware of support from governmental and voluntary agencies such as
the Citizens Advice Bureau in the UK
Issue repeat prescriptions to cover a longer duration—such as three months
Poor socioeconomic status
Illiteracy
Unemployment
Limited drug supply
Cost of drugs
Healthcare system
Book longer appointments
Training of healthcare assistants, nurses, doctors, and pharmacists to discuss adherence
Clinician-patient relationship
Lack of knowledge and training for healthcare providers
Inadequate time for consultation
Condition
Education through written and verbal information—shared decision making
Patient support groups
Peer support and education
Lack of symptoms
Chronic or incurable disease
No immediate consequences of stopping the drugs
Treatment
Simplify the regimen and minimise side effects through use of monotherapy, single pill
combination drugs, lower doses to prevent side effects, slow release formulations to
reduce dose frequency, trying other drugs in the same class or changing the class
Complex treatment regimens
Duration of treatment
Low drug tolerability and adverse effects of treatment such as dry cough
with angiotensin converting enzyme inhibitors inhibitors, ankle swelling with
calcium channel blockers, and electrolyte disturbances and gout with
diuretics
Patient
Patient education through written and verbal information
Motivational interviewing
Promoting self care through home monitoring
Using smart phone applications to set medication reminders and record their home
blood pressure, which could be shared electronically with their doctor
Patient’s knowledge of the disease
Patient’s perception of risk and awareness of costs and benefits of treatment
Non-acceptance of monitoring
Psychiatric illness
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Figure
Fig 1 QRISK2 score
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